Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic classifier in early-stage estrogen receptor-positive breast cancer

Catherine M. Kelly, Philip S. Bernard, Savitri Krishnamurthy, Bailiang Wang, Mark T.W. Ebbert, Roy R.L. Bastien, Kenneth M. Boucher, Elliana Young, Takayuki Iwamoto, Lajos Pusztai

Research output: Contribution to journalArticlepeer-review

59 Citations (Scopus)

Abstract

Purpose. To compare risk assignment by PAM50 Breast Cancer Intrinsic Classifier and Oncotype DX_Recur-rence Score (RS) in the same population. Methods. RNA was extracted from 151 estrogen receptor (ER) + stage I-II breast cancers and gene expression profiled using PAM50 "intrinsic" subtyping test. Results. One hundred eight cases had complete molecular information; 103 (95%) were classified as luminal A (n = 76) or luminal B (n = 27). Ninety-two percent (n = 98) had a low (n = 59) or intermediate (n = 39) RS. Among luminal A cancers, 70% had low (n = 53) and the remainder (n = 23) had an intermediate RS. Among luminal B cancers, nine were high (33%) and 13 were intermediate (48%) by the RS. Almost all cancers with a high RS were classified as luminal B (90%, n = 9). One high RS cancer was identified as basal-like and had low ER/ESR1 and low human epidermal growth factor receptor 2 (HER2) expression by quantitative polymerase chain reaction in both assays. The majority of low RS cases were luminal A (83%, n = 53). Importantly, half of the intermediate RS cancers were re-categorized as low risk luminal A subtype by PAM50. Conclusion. There is good agreement between the two assays for high (i.e., luminal B or RS > 31) and low (i.e., luminal B or RS < 18) prognostic risk assignment but PAM50 assigns more patients to the low risk category. About half of the intermediate RS group was reclassified as luminal A by PAM50.

Original languageEnglish
Pages (from-to)492-498
Number of pages7
JournalOncologist
Volume17
Issue number4
DOIs
Publication statusPublished - 2012
Externally publishedYes

Keywords

  • Breast cancer
  • Gene expression profiles
  • Oncotype DX®)
  • PAM50 assay
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic classifier <sup>™</sup> in early-stage estrogen receptor-positive breast cancer'. Together they form a unique fingerprint.

Cite this